Lake Street Capital Cuts Ekso Bionics (NASDAQ:EKSO) Price Target to $1.00

Ekso Bionics (NASDAQ:EKSO) had its price target lowered by Lake Street Capital from $2.00 to $1.00 in a report issued on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently issued reports on EKSO. StockNews.com began coverage on Ekso Bionics in a report on Monday. They set a “hold” rating for the company. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a research report on Tuesday.

Ekso Bionics Stock Down 8.0 %

Shares of Ekso Bionics stock opened at $0.40 on Tuesday. Ekso Bionics has a 1 year low of $0.37 and a 1 year high of $1.64. The business has a 50-day moving average of $0.61 and a two-hundred day moving average of $0.82. The company has a market capitalization of $8.86 million, a P/E ratio of -0.62 and a beta of 1.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $5.09 million during the quarter, compared to the consensus estimate of $5.05 million. As a group, equities analysts predict that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.